ASCO 2015 - Prostate Cancer

Viewing 1-11 of 11 articles

ASCO - TROG 03.06 and VCOG PR 01-03: The "timing of androgen deprivation therapy in prostate cancer patients with a rising PSA (TOAD)" collaborative randomised phase III trial - Session Highlights

ASCO - A phase III protocol of androgen suppression and radiotherapy vs. AS and RT followed by chemotherapy with docetaxel and prednisone for localized, high-risk prostate cancer - Session Highlights

ASCO - First-ever evidence shows adjuvant chemotherapy improves overall survival in high-risk, localized prostate cancer - Session Highlights

ASCO - Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE - Session Highlights

ASCO - Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration resistant prostate cancer - Session Highlights

ASCO - ARAMIS: Novel oral androgen receptor inhibitor ODM-201 enters phase 3 study in nmCRPC - Session Highlights

#ASCO15 - ODM-201 demonstrates high anticancer activity and favorable tolerability in the ARADES phase I/II trial in mCRPC - Session Highlights

ASCO 2015 - Long-term consequences of intermittent and continuous androgen deprivation in men with metastatic prostate cancer - Session Highlights

ASCO - Now or later: Optimal timing of docetaxel for metastatic prostate cancer: Early treatment with docetaxel chemotherapy - Session Highlights

ASCO - Now or later: Optimal timing of docetaxel for metastatic prostate cancer: Late treatment with docetaxel chemotherapy - Session Highlights

ASCO - Bottom line: Timing of treatment with docetaxel for men with advanced prostate cancer - Session Highlights

email news signup